Last reviewed · How we verify
TETA 4HCl formulation
TETA 4HCl formulation is a tetraethylammonium chloride, a potassium channel blocker.
TETA 4HCl formulation is a tetraethylammonium chloride, a potassium channel blocker. Used for Atrial fibrillation for stroke prevention.
At a glance
| Generic name | TETA 4HCl formulation |
|---|---|
| Sponsor | Orphalan |
| Drug class | Potassium channel blocker |
| Target | Potassium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
TETA 4HCl formulation works by blocking potassium channels, which can help to stabilize cardiac membranes and prevent arrhythmias. This mechanism is thought to be beneficial in the treatment of certain cardiac conditions.
Approved indications
- Atrial fibrillation for stroke prevention
Common side effects
- Hypokalemia
- QT interval prolongation
- Arrhythmias
Key clinical trials
- Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients. (PHASE3)
- Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride (PHASE2)
- Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily). (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |